Insider Selling: Alkermes (NASDAQ:ALKS) SVP Sells 6,000 Shares of Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $180,000.00. Following the transaction, the senior vice president directly owned 109,769 shares of the company’s stock, valued at $3,293,070. This represents a 5.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Alkermes Stock Up 0.3%

ALKS traded up $0.08 during trading on Wednesday, hitting $29.28. The company’s stock had a trading volume of 1,753,117 shares, compared to its average volume of 1,842,072. The firm has a market capitalization of $4.88 billion, a P/E ratio of 20.48, a PEG ratio of 7.28 and a beta of 0.53. Alkermes plc has a twelve month low of $25.17 and a twelve month high of $36.32. The stock’s fifty day moving average price is $31.60 and its 200-day moving average price is $30.24.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm had revenue of $384.55 million during the quarter, compared to analyst estimates of $380.44 million. During the same period last year, the business posted $1.05 EPS. The company’s revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Equities research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALKS. Sanctuary Advisors LLC grew its position in Alkermes by 2.7% during the 4th quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company’s stock worth $340,000 after acquiring an additional 315 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Alkermes by 3.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company’s stock valued at $289,000 after purchasing an additional 351 shares during the last quarter. Orion Porfolio Solutions LLC boosted its stake in shares of Alkermes by 4.5% during the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock valued at $263,000 after purchasing an additional 376 shares during the period. Horizon Investments LLC boosted its stake in shares of Alkermes by 0.9% during the third quarter. Horizon Investments LLC now owns 43,002 shares of the company’s stock valued at $1,290,000 after purchasing an additional 387 shares during the period. Finally, AMG National Trust Bank grew its holdings in shares of Alkermes by 0.6% in the third quarter. AMG National Trust Bank now owns 60,175 shares of the company’s stock worth $1,805,000 after purchasing an additional 388 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Royal Bank Of Canada reduced their price objective on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Wells Fargo & Company increased their price objective on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Wolfe Research started coverage on Alkermes in a research note on Monday, February 23rd. They set an “outperform” rating and a $45.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Alkermes has an average rating of “Moderate Buy” and a consensus price target of $44.07.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.